ArticleBlood cancer journal2025

Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients.

Jingyi Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.